Pediatrix Medical Group, Inc. (MD)

From the record

Pediatrix Medical Group, Inc.'s filings since 2017 show 1 warning event: a debt default or acceleration notice (8-K item 2.04, the latest 2020-12-21) (its current reports).

From the record

Pediatrix Medical Group, Inc.'s 10 filed years say what it did: revenue went from $3.2 billion in fiscal 2016 to $1.9 billion in fiscal 2025, down 5.5% a year; it rose in 6 of 9 years; the deepest fall was 47% from fiscal 2017 to fiscal 2018; net income was positive in 6 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Pediatrix Medical Group, Inc.'s diluted share count grew about 0.5% a year, and dividends and buybacks returned about 15% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 4 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Pediatrix Medical Group, Inc. earned about 19 cents of profit for every dollar of shareholders' money. Leverage: it owed about 61 cents per dollar of assets, and net share issuance: its share count grew 2.3% over the year (the filed statements).

From the record

Pediatrix Medical Group, Inc.'s standing among 22 graded names in its industry family: revenue of $1.9 billion in fiscal 2025 ranks in the bottom 20% by size; a net margin of 8.6% ranks in the top 25%; revenue growth of -1% a year over the last 3 filed years ranks in the bottom 2% (its annual reports).

From the record

Pediatrix Medical Group, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Ordan, Mark S (Chief Executive Officer, as filed), filing under that title since 2025-01-14, 1.8 years (bottom 24% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5 years (bottom 19%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 25%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Pediatrix Medical Group, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $375 million against debt of $571 million leaves -8.7% of its assets as net cash, top 31% of its family; cash from operations less capital spending is 14.2% of revenue (top 2%) (its annual report).

From the record

Pediatrix Medical Group, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -1% a year over the last three filed years against -5.5% over all 10, speeding up (top 30% of its family); the newest year grew -4.9% (bottom 2%) (its annual reports). Pediatrix Medical Group, Inc. reported 3 product lines in fiscal 2025: Health Care Patient Service at $1.6 billion (85%), Hospitals Contracts at $271 million (14%), Product and Service Other at $12 million (1%); 1 of 3 grew against the year before (its annual report).

From the record

Pediatrix Medical Group, Inc.'s newest year against its own record: revenue of $1.9 billion in fiscal 2025 came in 5.9% below the $2.0 billion its prior three years' pace pointed to (bottom 2% of its family); net income of $165 million against a prior three-year average of $31 million (top 2%); a net margin of 8.6% against -1.5% before (top 7%) (its annual reports).